Neurotoxin Mechanisms and Processes Relevant to Parkinson's Disease: An Update

被引:51
|
作者
Segura-Aguilar, Juan [1 ]
Kostrzewa, Richard M. [2 ]
机构
[1] Univ Chile, Fac Med, Mol & Clin Pharmacol, ICBM, Santiago 7, Chile
[2] E Tennessee State Univ, James H Quillen Coll Med, Dept Biomed Sci, Johnson City, TN 37614 USA
关键词
Parkinson's disease; 6-Hydroxydopamine; MPP+; MPTP; Ortho-quinones; Reactive oxygen species; Rotenone; NEURONAL CELL-DEATH; MPTP MOUSE MODEL; PROTECTS DOPAMINERGIC-NEURONS; ENDOPLASMIC-RETICULUM STRESS; NF-KAPPA-B; NEUROBLASTOMA SH-SY5Y CELLS; MITOCHONDRIAL COMPLEX-I; MPP+-INDUCED APOPTOSIS; PPAR-GAMMA AGONIST; 6-HYDROXYDOPAMINE-INDUCED OXIDATIVE STRESS;
D O I
10.1007/s12640-015-9519-y
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The molecular mechanism responsible for degenerative process in the nigrostriatal dopaminergic system in Parkinson's disease (PD) remains unknown. One major advance in this field has been the discovery of several genes associated to familial PD, including alpha synuclein, parkin, LRRK2, etc., thereby providing important insight toward basic research approaches. There is an consensus in neurodegenerative research that mitochon dria dysfunction, protein degradation dysfunction, aggregation of alpha synuclein to neurotoxic oligomers, oxidative and endoplasmic reticulum stress, and neuroinflammation are involved in degeneration of the neuromelanin-containing dopaminergic neurons that are lost in the disease. An update of the mechanisms relating to neurotoxins that are used to produce preclinical models of ParkinsonA ' s disease is presented. 6-Hydroxydopamine, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and rotenone have been the most wisely used neurotoxins to delve into mechanisms involved in the loss of dopaminergic neurons containing neuromelanin. Neurotoxins generated from dopamine oxidation during neuromelanin formation are likewise reviewed, as this pathway replicates neurotoxin-induced cellular oxidative stress, inactivation of key proteins related to mitochondria and protein degradation dysfunction, and formation of neurotoxic aggregates of alpha synuclein. This survey of neurotoxin modeling-highlighting newer technologies and implicating a variety of processes and pathways related to mechanisms attending PD-is focused on research studies from 2012 to 2014.
引用
收藏
页码:328 / 354
页数:27
相关论文
共 50 条
  • [21] Epidemiology of Parkinson's Disease: An Update
    Deliz, Juan R.
    Tanner, Caroline M.
    Gonzalez-Latapi, Paulina
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2024, 24 (06) : 163 - 179
  • [22] Update on the pathogenesis of Parkinson's disease
    Schulz, Joerg B.
    JOURNAL OF NEUROLOGY, 2008, 255 (Suppl 5) : 3 - 7
  • [23] An update on the treatment of Parkinson's disease
    Jankovic, Joseph
    MOUNT SINAI JOURNAL OF MEDICINE, 2006, 73 (04): : 682 - 689
  • [24] Update on surgery for Parkinson's disease
    Volkmann, Jens
    CURRENT OPINION IN NEUROLOGY, 2007, 20 (04) : 465 - 469
  • [25] Inflammation in Parkinson's disease: An update
    Smith, Paul F.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (05) : 478 - 484
  • [26] Pramipexole and Parkinson's disease, an update
    Martinez-Corral, M.
    Kulisevsky, J.
    REVISTA DE NEUROLOGIA, 2008, 46 (01) : 49 - 52
  • [27] Parkinson's Disease with Fatigue: Clinical Characteristics and Potential Mechanisms Relevant to α-Synuclein Oligomer
    Zuo, Li-Jun
    Yu, Shu-Yang
    Wang, Fang
    Hu, Yang
    Piao, Ying-Shan
    Du, Yang
    Lian, Teng-Hong
    Wang, Rui-Dan
    Yu, Qiu-Jin
    Wang, Ya-Jie
    Wang, Xiao-Min
    Chan, Piu
    Chen, Sheng-Di
    Wang, Yongjun
    Zhang, Wei
    JOURNAL OF CLINICAL NEUROLOGY, 2016, 12 (02): : 172 - 180
  • [28] The effects of viral priming on neurotoxin induced neurodegeneration and synapse dysfunction in cell culture models relevant to Parkinson's disease
    Olsen, L. K.
    Dowd, E.
    McKernan, D.
    MOVEMENT DISORDERS, 2016, 31 : S276 - S277
  • [29] Paraquat is a model environmental neurotoxin for studying Parkinson's disease
    Sun, AY
    Li, XW
    NEUROTOXIC FACTORS IN PARKINSON'S DISEASE AND RELATED DISORDERS, 2000, : 247 - 257
  • [30] Use of Botulinum Neurotoxin in Parkinson's Disease: A Critical Appraisal
    Jost, Wolfgang H.
    TOXINS, 2021, 13 (02)